Inclusion Criteria:  Adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding; Those need capsule endoscopy because the recurring GI symptoms cannot be explained by other imaging methods; Those can understand and accept this study protocol and voluntarily sign an informed consent.  Exclusion Criteria:  Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule; Patient with known gastrointestinal motility disorders; Patient with known or suspected gastrointestinal obstruction, stenosis or fistula; Patient with known or suspected delayed gastric emptying; Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions; Patient has any allergy or other known contraindication or intolerance to the medications used in the study; Patient has any condition, which precludes compliance with study and/or device instructions; Women who are either pregnant or nursing at the time of screening; Concurrent participation in another clinical trial using any investigational drug or device; Patient suffers from a life-threatening condition; Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters; Patients with pace-maker or implantable cardioverter other implantable electronic medical device; Patient with an easily magnetized metal part; Patient requires endoscopic placement of the capsule; Others considered by the investigator not suitable for this study.